FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938623428> ?p ?o ?g. }

• W2938623428 abstract "Background: Obesity is a growing pandemic that is associated with multiple cardiovascular disease (CVD) risk factors such as hypertension, diabetes, dyslipidemia and obstructive sleep apnea. With the increase in obesity rates where nearly two thirds of Americans are either obese or overweight, there has been an increase in the use of pharmacological therapy weight loss. While these therapies have shown benefit in weight reduction, the clinical impact these pharmacological agents on overall CVD outcomes has yet to be determined. Aim: We aimed to assess the effect of pharmacological agents used for weight reduction on CVD risk and allcause mortality. Methods: We conducted a meta-analysis of peer-reviewed literature that evaluated the impact of anti-obesity drugs on cardiovascular outcomes. Key words used included: “orlistat”, “lorcaserin”, “phentermine/topiramate” or “naltrexone/bupropion” and “cardiovascular outcomes” among others. We reviewed 791 articles, only 47 studies were randomized controlled trials and only 7 studies fulfilled all the inclusion criteria including, quantitative data on cardiovascular risk factors such as, Hemoglobin A1C (A1C), changes in body mass index (BMI), blood pressure and CVD morbidity and mortality. Data was retrieved from these studies and evaluated with comprehensive meta-analysis software® to assess pooled effects for medical management versus placebo. Results: There were 7 studies included in the final analysis, with a total of 18,598 subjects, of which 8,685 were in the intervention (INT) group and 9,913 in the control (CTRL) group. For all cause mortality, there were 45 events in the INT and 55 in the CTRL groups, suggesting no significant difference between the two groups (OR: 0.843, 95%CI: 0.571-1.244, Z: -0.860, P: 0.390). For CVD mortality, there were 17 events in the INT and 36 events in the CTRL groups suggesting a significant mortality benefit in the INT group (OR:0.496, 95% CI: 0.282-0.873, Z: -2.433, P: 0.015). There was a significant absolute reduction in A1C in the INT group (Hg: -0.238, 95%CI: -0.291 to -0.186, Z: -8.937, P< 0.001). The percentage weight reduction was significantly higher for the INT group compared to the CTRL group (Hg: -0.431, 95%CI: -0.477 to -0.385, Z: -18.472, P< 0.001) and the blood pressure reduction was higher for the INT group compared to the CTRL group. (Hg: -0.052, 95%CI: -0.101- -0.003, Z: -2.086, P: 0.037). The heterogeneity observed for our meta analysis is Q: 1.884, df: 6, P: 0.930. Conclusions: Our study demonstrated the favorable and significant effect of pharmacological weight reduction strategies on weight loss, blood pressure reduction, glycemic control (A1C reduction), and CVD mortality. While weight loss without pharmacological means has been shown to reduce CVD risk, the mechanism by which weight loss medications impact CVD risk reduction could be a direct effect of these agents or merely an effect of weight reduction itself. Weight loss has been noted to modify risk factors via improving insulin sensitivity, reducing inflammation, decreasing blood pressure and modifying the lipid profile, In addition, the mechanism of action of the medications are not directly anti-inflammatory, and do not directly modify insulin sensitivity, blood pressure or the lipid profile. Thus, it is most likely that the benefit on cardiovascular disease from these therapies is via weight reduction and not direct medication effect. Given the limited efficacy of the lifestyle modification on sustained weight loss and the surgical risk and limited availability of bariatric surgical options. Our data suggests pharmacological weight loss therapy may be a valuable treatment option to reduce CVD risk in obese patients. Further research is needed to clarify the effects these therapies on overall mortality and evaluate the mechanisms by which these medications reduce CVD risk factors and mortality." @default.
• W2938623428 created "2019-04-25" @default.
• W2938623428 creator A5004415432 @default.
• W2938623428 creator A5018335370 @default.
• W2938623428 creator A5030900258 @default.
• W2938623428 creator A5057962046 @default.
• W2938623428 creator A5058770919 @default.
• W2938623428 creator A5066060032 @default.
• W2938623428 creator A5071480133 @default.
• W2938623428 creator A5073111085 @default.
• W2938623428 creator A5077717542 @default.
• W2938623428 creator A5078061209 @default.
• W2938623428 date "2019-01-21" @default.
• W2938623428 modified "2023-09-30" @default.
• W2938623428 title "Cardiovascular Risk Reduction Associated with Pharmacological Weight Loss: A Meta-Analysis" @default.
• W2938623428 cites W1976303326 @default.
• W2938623428 cites W1978795840 @default.
• W2938623428 cites W1978947696 @default.
• W2938623428 cites W1983674364 @default.
• W2938623428 cites W1984921150 @default.
• W2938623428 cites W1985399572 @default.
• W2938623428 cites W1987588766 @default.
• W2938623428 cites W2020982355 @default.
• W2938623428 cites W2069680000 @default.
• W2938623428 cites W2070616232 @default.
• W2938623428 cites W2087780912 @default.
• W2938623428 cites W2094384568 @default.
• W2938623428 cites W2102170193 @default.
• W2938623428 cites W2103916483 @default.
• W2938623428 cites W2107328434 @default.
• W2938623428 cites W2109342401 @default.
• W2938623428 cites W2125239733 @default.
• W2938623428 cites W2126470550 @default.
• W2938623428 cites W2130210878 @default.
• W2938623428 cites W2130421055 @default.
• W2938623428 cites W2131378136 @default.
• W2938623428 cites W2132428032 @default.
• W2938623428 cites W2133059852 @default.
• W2938623428 cites W2148449799 @default.
• W2938623428 cites W2150000105 @default.
• W2938623428 cites W2294274888 @default.
• W2938623428 cites W2411583672 @default.
• W2938623428 cites W2472539201 @default.
• W2938623428 cites W2499426752 @default.
• W2938623428 cites W2588237306 @default.
• W2938623428 cites W269351672 @default.
• W2938623428 cites W2770976506 @default.
• W2938623428 cites W1543297732 @default.
• W2938623428 doi "https://doi.org/10.15344/2456-8007/2019/131" @default.
• W2938623428 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6497407" @default.
• W2938623428 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31058246" @default.
• W2938623428 hasPublicationYear "2019" @default.
• W2938623428 type Work @default.
• W2938623428 sameAs 2938623428 @default.
• W2938623428 citedByCount "26" @default.
• W2938623428 countsByYear W29386234282019 @default.
• W2938623428 countsByYear W29386234282020 @default.
• W2938623428 countsByYear W29386234282021 @default.
• W2938623428 countsByYear W29386234282022 @default.
• W2938623428 countsByYear W29386234282023 @default.
• W2938623428 crossrefType "journal-article" @default.
• W2938623428 hasAuthorship W2938623428A5004415432 @default.
• W2938623428 hasAuthorship W2938623428A5018335370 @default.
• W2938623428 hasAuthorship W2938623428A5030900258 @default.
• W2938623428 hasAuthorship W2938623428A5057962046 @default.
• W2938623428 hasAuthorship W2938623428A5058770919 @default.
• W2938623428 hasAuthorship W2938623428A5066060032 @default.
• W2938623428 hasAuthorship W2938623428A5071480133 @default.
• W2938623428 hasAuthorship W2938623428A5073111085 @default.
• W2938623428 hasAuthorship W2938623428A5077717542 @default.
• W2938623428 hasAuthorship W2938623428A5078061209 @default.
• W2938623428 hasBestOaLocation W29386234281 @default.
• W2938623428 hasConcept C118552586 @default.
• W2938623428 hasConcept C126322002 @default.
• W2938623428 hasConcept C134018914 @default.
• W2938623428 hasConcept C168563851 @default.
• W2938623428 hasConcept C2777683783 @default.
• W2938623428 hasConcept C2778096610 @default.
• W2938623428 hasConcept C2778186239 @default.
• W2938623428 hasConcept C2778456266 @default.
• W2938623428 hasConcept C2780221984 @default.
• W2938623428 hasConcept C2780586474 @default.
• W2938623428 hasConcept C2780780548 @default.
• W2938623428 hasConcept C511355011 @default.
• W2938623428 hasConcept C544821477 @default.
• W2938623428 hasConcept C555293320 @default.
• W2938623428 hasConcept C71924100 @default.
• W2938623428 hasConcept C95190672 @default.
• W2938623428 hasConceptScore W2938623428C118552586 @default.
• W2938623428 hasConceptScore W2938623428C126322002 @default.
• W2938623428 hasConceptScore W2938623428C134018914 @default.
• W2938623428 hasConceptScore W2938623428C168563851 @default.
• W2938623428 hasConceptScore W2938623428C2777683783 @default.
• W2938623428 hasConceptScore W2938623428C2778096610 @default.
• W2938623428 hasConceptScore W2938623428C2778186239 @default.
• W2938623428 hasConceptScore W2938623428C2778456266 @default.
• W2938623428 hasConceptScore W2938623428C2780221984 @default.
• W2938623428 hasConceptScore W2938623428C2780586474 @default.
• W2938623428 hasConceptScore W2938623428C2780780548 @default.
• W2938623428 hasConceptScore W2938623428C511355011 @default.

• next